Monday, May 31, 2021

Glenmark expects 10-12% sales growth in FY22, anticipates value unlock of its RD business

Glenmark expects 10-12% sales growth in FY22, anticipates value unlock of its RD business Sale of anti-COVID drug Fabiflu and other products fire Q1 revenues; the company spends little over $100 million annually on innovation RD business, bigger than most of its peers, developing a potential pipeline of drug assets

from Moneycontrol Business News https://ift.tt/3i62RHe
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

US stock: S&P 500 ends lower as investors weigh data, Middle East tensions

The S&P 500's streak came to an end, falling from its peak as weaker retail sales suggested caution among consumers. Despite a stron...